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Abstract
PIN1-mediated substrate isomerization plays a role in the repair of DNA double-strand breaks. We 
hypothesized that genetic polymorphisms in PIN1-related pathways may affect tumor sensitivity to 
oxaliplatin or irinotecan in metastatic colorectal cancer (mCRC) patients. We analyzed genomic 
DNA from five cohorts of mCRC patients (total 950) treated with different first-line treatments: 
oxaliplatin cohorts 1 (n=146) and 2 (n=70); irinotecan cohorts 1 (n=228) and 2 (n=276); and 
combination cohort (n=230). Single nucleotide polymorphisms of candidate genes were analyzed 
by PCR-based direct sequencing. In the oxaliplatin cohort 1, patients carrying any PIN1 
rs2233678 C allele had shorter progression-free survival (PFS) and overall survival (OS) than the 
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G/G variant (PFS, 7.4 vs. 15.0 months, hazard ratio [HR] 3.24, P<0.001; OS, 16.9 vs. 31.5 
months, HR: 2.38, P=0.003). In contrast, patients with C allele had longer median PFS than 
patients with G/G (11.9 vs. 9.4 months, HR: 0.64, 95%CI: 0.45–0.91, P=0.009) in the irinotecan 
cohort 1. No significant differences were observed in the combination cohort. In comparison 
between the irinotecan cohort 1 and combination cohort, the patients carrying the G/G variant 
benefit greatly from the combination compared with irinotecan-based regimen (PFS, 11.6 vs. 9.4 
months, HR 0.61, 95%CI: 0.47–0.78, P<0.001; OS, 30.6 vs. 24.0 months, HR 0.79, 95%CI: 0.62–
1.02, P=0.060), while no significant difference was shown in any C allele. Germline PIN1 
polymorphisms may predict clinical outcomes in mCRC patients receiving oxaliplatin- or 
irinotecan-based therapy, and identify specific populations favorable to oxaliplatin plus irinotecan 
combination therapy.
Introduction
The never-in-mitosis-gene-a (NIMA) kinases are a family of serine/threonine kinases that 
play essential roles in mitotic entry by modulating the cell cycle in both Aspergillus nidulans 
and human cells.1–3 Overexpression of NIMA promotes progression of the cell cycle 
irrespective of the cell cycle phase, while inactivation of NIMA reversibly induces late G2 
arrest.4 Serine/threonine (S/T) phosphorylation regulates the function of proteins by 
inducing conformational changes. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 
(PIN1) interacts with NIMA in a manner that correlates with cell cycle progression, cellular 
proliferation, and neoplastic transformation. PIN1 binds to and isomerizes specific 
phosphorylated S/T-proline motifs, resulting in conformational changes in a subset of target 
proteins. The PIN1-induced conformational changes affect the function of its substrates 
through a post-phosphorylation regulatory mechanism, leading to enhanced or suppressed 
phosphorylation in cell signaling.5
PIN1 is also involved in the repair of DNA double-strand breaks (DSBs) as part of the DNA 
damage response (DDR), which maintains genomic integrity and reduces the risk of 
tumorigenesis.6,7 The DDR activates DNA repair and regulates cell cycle checkpoint 
pathways, leading to cell cycle arrest or apoptosis.8 TP53 is a tumor suppressor gene that 
transcriptionally regulates genes involved in cell cycle checkpoints, genomic stability, and 
apoptosis.9 As part of the checkpoints, DNA damage triggers PIN1 isomerization of p53, 
which directs the transcriptional activity of p53 toward cell cycle arrest or apoptosis 
depending on the degree of DNA damage.10,11 In addition, PIN1 inhibits the ubiquitination 
of p53 by mouse double minute 2 homolog (Mdm2).12 Homologous recombination is a 
crucial DNA repair pathway triggered by DSBs in the late S and G2 phases of the cell cycle. 
Isomerization of CtIP by PIN1 results in diminished DSB repair by restricting DNA end-
resection (Figure 1A). Furthermore, PIN1 appears to restrict homologous recombination and 
promote another DNA repair pathway non-homologous end-joining (NHEJ) under DSBs via 
isomerization of CtIP.6,13
Casein kinase 2 (CK2) is a tetrameric protein consisting of two catalytic (CK2α/2α′) and 
two regulatory (CK2β) subunits.14 CK2 is a highly conserved serine/threonine protein 
kinase that regulates cell viability, cell proliferation, and signal transduction by 
Suenaga et al. Page 2
Pharmacogenomics J. Author manuscript; available in PMC 2018 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
phosphorylating numerous cellular targets.15–17 PIN1 interacts with CK2α/2α′, especially 
phosphorylated CK2α, but not with CK2β. PIN1-mediated isomerization of CK2α regulates 
the hyperphosphorylation and activity of topoisomerase I (Top1), an enzyme that unwinds 
the DNA double helix and is the target of irinotecan 18,19 (Figure 1B).
As key components of current standard treatments for colorectal cancer (CRC),20 oxaliplatin 
is a platinum compound that crosslinks DNA, whereas irinotecan inhibits Top1.21,22 
Although both agents induce DNA damage, we speculated that they may inflict different 
degrees of damage, and oxaliplatin would be predicted to have the greater effect. In this 
study, we determined whether gene polymorphisms in PIN1-related pathway components 
could predict the efficacy of oxaliplatin- and irinotecan-based treatments and their 
combination therapy in patients with metastatic CRC (mCRC).
Materials and methods
Study design and patients
We investigated five independent cohorts of 950 patients with mCRC who received different 
first-line treatments. Oxaliplatin cohort 1 (Ox-cohort 1) consisted of 146 patients who 
received FOLFOX ± bevacizumab treatment at the Cancer Institute Hospital (Tokyo, Japan) 
as discovery.23 Oxaliplatin cohort 2 (Ox-cohort 2) consisted of 70 patients in a retrospective 
cohort who received first-line FOLFOX or XELOX + bevacizumab treatment as validation 
(Tokyo, Japan). Irinotecan cohort 1 (Iri-cohort 1) of 228 patients received FOLFIRI + 
bevacizumab treatment (TRIBE arm A) in the randomized, open-label, phase III TRIBE trial 
as discovery.24 Irinotecan cohort 2 (Iri-cohort 2) of 276 patients received FOLFIRI + 
bevacizumab treatment (FIRE-3 arm B) in the randomized, open-label, phase III FIRE-3 
trial.25 Combination cohort (Ox + Iri-cohort) consisted of 230 patients who received 
FOLFOXIRI + bevacizumab treatment (TRIBE arm B) in the TRIBE trial.24 Eligible 
patients had a histologically confirmed diagnosis of mCRC, had measurable or evaluable 
disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, had no 
prior treatment for metastatic disease, and provided signed informed consent. FOLFOX ± 
bevacizumab treatment (oxaliplatin 85 mg/m2, 5-fluorouracil [5-FU] bolus 400 mg/m2, 5-FU 
infusion 2400 mg/m2, levofolinate calcium 200 mg/m2, with or without bevacizumab 5 
mg/kg) was administered every 2 weeks. XELOX + bevacizumab treatment (oxaliplatin 130 
mg/m2, capecitabine 1,000 mg/m2 given twice daily from evening of day 1 to morning of 
day 15, with or without bevacizumab 5 mg/kg) was administered every 3 weeks. FOLFIRI + 
bevacizumab treatment (irinotecan 180 mg/m2, 5-FU bolus 400 mg/m2, 5-FU infusion 2400 
mg/m2, leucovorin 200 mg/m2, bevacizumab 5 mg/kg) was administered every 2 weeks. 
FOLFOXIRI + bevacizumab treatment (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, 5-FU 
bolus 400 mg/m2, 5-FU infusion 3200 mg/m2, leucovorin 200 mg/m2, with or without 
bevacizumab 5 mg/kg) was administered every 2 weeks. Treatment was continued until any 
of the following occurred: disease progression, unmanageable toxicity, or patient refusal. We 
were fully compliant with the Reporting Recommendations for Tumor Marker Prognostic 
Studies (REMARK) guidelines. Tissue analysis was approved by the Institutional Review 
Board of each institute and was conducted at the University of Southern California/Norris 
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Comprehensive Cancer Center in accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines.
Single nucleotide polymorphism (SNP) selection
The eight candidate SNPs examined in this study were present in seven genes: PIN1; TP53; 
CHE1/apoptosis antagonizing transcription factor (AATF); casein kinase 2, alpha 1 
polypeptide (CSNK2A1); casein kinase 2, beta polypeptide (CSNK2B); TOP1; and CTIP/
retinoblastoma binding protein 8 (RBBP8), and were selected by the following criteria: (i) 
SNPs revealed to be of biological significance according to a literature review; (ii) tagged 
SNPs using the HapMap genotype data with r2 threshold of 0.8: http://snpinfo.niehs.nih.gov/
snpinfo/snptag.htm; or (iii) SNPs with a cut-off for minor allele frequency of at least 10% in 
both Caucasians and East Asians (in the Ensembl Genome Browser: http://
uswest.ensembl.org/index.html). Functional significance was predicted based on the 
functional SNP (F-SNP) database: http://compbio.cs.queensu.ca/F-SNP/ (Supplementary 
Table S1).
DNA extraction and genotyping
Genomic DNA was isolated from peripheral whole blood samples from the patients in the 
TRIBE cohorts and from formalin-fixed paraffin-embedded tissues from the patients in the 
Ox-cohort 1, Ox-cohort 2 and the Iri-cohort 2. DNA was extracted using a QIAmp Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Genotyping of the 
selected SNPs was performed by PCR-based direct DNA sequence analysis using an ABI 
3100A Capillary Genetic Analyzer and Sequencing Scanner v1.0 (Applied Biosystems, Life 
Technologies, Grand Island, NY, USA). The extracted DNA samples were amplified using 
forward and reverse primers for each SNP. For quality control purposes, 10% of the samples 
were randomly selected and analyzed for each SNP by direct DNA sequencing; this yielded 
genotype concordance rates of at least 99%. SNP analysis was performed using an ABI 
Sequencing Scanner v1.0 (Applied Biosystems) and carried out by investigators blinded to 
the patients’ clinical data.
Immunohistochemistry
To determine whether the expression of p53 correlated with the PIN1 polymorphisms, we 
performed immunohistochemical staining of formalin-fixed, paraffin-embedded tumor 
sections using an anti-p53 protein antibody (D0-7; DAKO, Santa Clara, CA, USA). A 
pathologist assessed 131 of 146 samples from the Ox-cohort 1 who received oxaliplatin-
based treatment at the Cancer Institute Hospital in Japan. Tumors from the remaining 15 
patients were not analyzed due to a lack of tissue. Three patterns of p53 staining were 
identified: strong nuclear staining was defined as ‘overexpression (high expression)’, 
moderate or mild nuclear staining was defined as ‘wild-type expression’, and no nuclear 
staining was defined as ‘loss (low expression)’.
Statistical analysis
The study endpoints were progression-free survival (PFS), overall survival (OS), and tumor 
response. PFS was defined as the interval between the date of starting treatment (oxaliplatin 
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cohorts) or randomization (TRIBE and FIRE-3 cohorts) and the date of confirmed disease 
progression or death. For patients who had no disease progression or who died, PFS was 
censored at the date of last follow-up. OS was calculated from the date of starting treatment 
(Ox-cohorts 1 and 2) or randomization (TRIBE and FIRE-3 cohorts) until the date of death 
from any cause. For patients who were lost to follow-up, data were censored on the date 
when the patient was last confirmed to be alive. The objective response rate was calculated 
from the number of patients who achieved complete response (CR) and partial response 
(PR) to treatment, according to RECIST v1.0, among all patients whose tumor responses 
were evaluated. The patient baseline characteristics were compared across cohorts using 
Chi-square and Kruskal–Wallis tests, as appropriate. The allelic distribution of SNPs by 
ethnicity for deviation from the Hardy–Weinberg equilibrium and the allelic frequencies of 
the SNPs were examined by exact tests. The associations between SNPs and baseline 
characteristics were examined by Fisher’s exact test. Kaplan–Meier curves were constructed 
and analyzed by the log-rank test to estimate the associations between the candidate SNPs 
and PFS or OS. A multivariable Cox proportional hazards model was used to adjust for 
factors influencing the association between SNPs and PFS or OS. Baseline patient 
demographic and clinical characteristics that were significantly associated with PFS or OS at 
P < 0.1 were included in the multivariable analyses. Fisher’s exact test was used to examine 
associations between SNPs and tumor responses. Co-dominant, dominant, or recessive 
genetic models were used for SNPs, because no true model has yet been established. The 
study had 80% power to detect a minimum hazard ratio (HR) of 1.77 to 2.03 for the 
association between a SNP and PFS when the minor allele frequencies ranged from 0.1 to 
0.4 in the Ox-cohort 1 (n = 146, PFS events: 98) using a dominant model and a two-sided 
log-rank test at the 0.05 level, and 80% power to detect a minimum HR of 1.53 to 1.72 for 
the association between a SNP and PFS when the minor allele frequencies ranged from 0.1 
to 0.4 in the Iri-cohort 1 (n = 228, PFS events: 174) using a dominant model and a two-sided 
log-rank test at the 0.05 level. The power for detecting a minimum HR of 1.77 to 2.03 was at 
least 44% for the same SNPs with the same minor allele frequencies in the Ox-cohort 2 (n = 
70, PFS events: 43), 97% in the irinotecan cohort 2 (n = 276, PFS events: 236), and 93% in 
the combination cohort (n = 230, PFS events: 162) using the same tests. All analyses were 
carried out with SAS 9.4 software (SAS Institute, Cary, NC, USA). All tests were two-sided 
at a significance level of 0.05.
Results
Baseline demographics and clinical characteristics
The baseline characteristics of the five cohorts are summarized in Table 1. The allelic 
frequencies and genotype distribution of each SNP met the reported results for Japanese or 
Caucasian populations, and all candidate SNPs were genotyped at a success rate of ≥93% in 
all cohorts, based on the quantity or quality of the extracted genomic DNA. The allelic 
frequencies for all candidate SNPs analyzed in this study were within the Hardy–Weinberg 
equilibrium (P>0.05) in all cohorts.
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Candidate polymorphisms and clinical outcomes in oxaliplatin cohorts
Univariate analysis of the Ox-cohort 1 revealed that patients carrying any C allele in PIN1 
rs2233678 had significantly shorter PFS (7.4 vs. 15.0 months, HR 3.24, 95% CI 1.60–6.54, 
P<0.001) and OS (16.9 vs. 31.5 months, HR 2.38, 95% CI 1.32–4.30, P=0.003) than patients 
with the G/G variant. These effects remained significant in the multivariable analysis at 
P=0.009 and P = 0.044 for PFS and OS, respectively. Regarding tumor response, patients 
with the C/C variant in TP53 rs1042522 achieved a significantly higher response rate than 
patients with any G allele (74% vs. 46%, P=0.001) (Figure 2A; Table 2; Supplementary 
Table S2). In the Ox-cohort 2, patients carrying the PIN1 rs2233678 G/C allele had shorter 
OS than patients with the G/G variant (17.3 vs. 36.0 months, HR 2.43, 95% CI 0.83–7.15, 
P=0.087); in the multivariable model, the effect remained marginally significant (HR 3.01, 
95% CI 0.98–9.20, P=0.054) (Table 2).
Candidate polymorphisms and clinical outcomes in irinotecan cohorts
Univariate analysis of the Iri-cohort 1 revealed that patients carrying any C allele in PIN1 
rs2233678 had significantly longer PFS (11.9 vs. 9.4 months, HR 0.64, 95% CI 0.45–0.91, 
P=0.009) than patients with the G/G variant. Although the patients carrying a C allele also 
had longer OS, the difference did not reach the level of statistical significance (31.6 vs. 24.0 
months, HR 0.79, 95% CI 0.56–1.11, P = 0.17) (Figure 2B). In the multivariable analysis, 
PIN1 rs2233678 remained significantly associated with PFS (HR 0.61, 95% CI 0.38–0.96, 
P=0.033) (Table 2; Supplementary Table S3). In the analysis of tumor response, any PIN1 
rs2233678 C allele variant was significantly associated with better tumor response compared 
with the G/G variant (Fisher’s exact P=0.011). In the Iri-cohort 2, no significant associations 
were observed between SNPs and tumor response or outcomes (Table 2).
Candidate polymorphisms and clinical outcomes in combination (Ox + Iri) cohort
Univariate and multivariate analyses showed no significant differences between SNPs and 
PFS, OS, or tumor response (Table 2; Figure 2C).
Comparison between FOLFIRI + bevacizumab and FOLFOXIRI + bevacizumab according to 
PIN1 polymorphisms in TRIBE trial
In comparison of the Iri-cohort 1 and Ox + Iri-cohort (TRIBE arm A vs. B), the patients with 
the G/G variant in PIN1 rs2233678 benefitted from FOLFOXIRI + bevacizumab compared 
with FOLFIRI + bevacizumab for clinical outcomes (PFS, 11.6 vs. 9.4 months, HR 0.61, 
95%CI: 0.47–0.78, P<0.001; OS, 30.6 vs. 24.0 months, HR 0.79, 95%CI: 0.62–1.02, 
P=0.060); while no significant survival benefit was shown in any C allele (Figures 3A and 
3B; Supplementary Table S4).
Associations between p53 immunohistochemistry and PIN1 polymorphisms
Patients in the Ox-cohort 1 were assigned to three groups based on immunohistochemical 
staining for p53 in 131 tissue samples: 69 patients showed high expression, 37 showed wild-
type expression, and 25 showed low expression. Patients in the wild-type or low expression 
groups had longer PFS and OS, but the effects were not significant (Supplementary Table 
S5). Interaction analyses between p53 staining status and TP53 rs1042522 or PIN1 
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rs2233678 were performed. Interaction terms for p53 and SNPs were included in the 
multivariable model adjusted for baseline characteristics and estimated using the maximum 
likelihood test. However, no significant interactions were observed between p53 expression 
and these SNPs.
Discussion
We report here the first evidence that PIN1 gene polymorphisms may influence the 
antitumor activity of oxaliplatin in first-line treatment for mCRC. The SNPs potentially 
predicted the outcomes for efficacy of oxaliplatin-based treatment and additional effect of 
oxaliplatin in combination treatment with irinotecan.
In the TRIBE trial, first-line FOLFOXIRI + bevacizumab significantly improved PFS and 
OS compared with FOLFIRI + bevacizumab in mCRC patients.24 To our knowledge, there 
have been no reports of useful biological markers that can distinguish clinical outcomes 
between them. In addition, it remains unknown whether the antitumor effect of the 
combination regimen is based on a synergistic action. .
Recent data in a review showed that PIN1 acts as a post-phosphorylation regulator of 
biological function of its substrate proteins and alters their conformation.5,26 The 
conformational changes can modulate biological activity, bioavailability, phosphorylation 
status, protein-protein interactions, protein stability, and subcellular localization, leading to 
regulation of various cellular events such as transcriptional regulation, cell proliferation, and 
mitosis.27 Lu et al. analyzed the allele-specific effects of PIN1 rs2233678 variants on 
promoter activity using a luciferase reporter assay, and showed that the G allele was more 
highly associated with PIN1 gene expression compared with the C allele. The authors 
suggested that the change from G to C might diminish binding of regulatory proteins to the 
PIN1 promoter, although differences in PIN1 mRNA levels in cells with different PIN1 
rs2233678 genotypes were not assessed. In addition, the C allele was associated with a 
decreased risk of squamous cell carcinoma of the head and neck, indicating that the G/G 
variant was a high risk factor.28
Our data showed that the dominant PIN1 rs2233678 G/G variant was associated with the 
outcome of oxaliplatin-based treatment; that is, G/G was favorable for oxaliplatin treatment. 
To our knowledge, there is currently no strong evidence of an association between PIN1 
polymorphisms and sensitivity to chemotherapeutic agents. The findings from the functional 
analysis described above shed light on the role of PIN1 in the DDR to oxaliplatin treatment.
28
 The PIN1-mediated conformational change in CtIP restricts homologous recombination 
while simultaneously promoting NHEJ. A recent in vitro study demonstrated that depletion 
of PIN1 significantly decreased NHEJ frequency, whereas PIN1 overexpression markedly 
reduced homologous recombination by diminishing the formation of single-stranded DNA.
13
 These data support our findings of better outcomes for patients with the PIN1 rs2233678 
G/G variant following oxaliplatin-based treatment, and suggest the possibility that the high 
expression of PIN1 in these patients inhibits CtIP and thus inactivates homologous 
recombination (Figure 1C). We found no interaction effects between p53 staining and TP53 
rs1042522 and PIN1 rs2233678, suggesting that the PIN1-induced change in conformation 
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of p53 does not affect its expression. A recent study also investigated the correlation 
between TP53 rs1042522 alleles and p53 expression by immunohistochemical staining, and 
observed no association.29 However, the diverse and varied effects of oncologic signaling 
resulting from a PIN1-induced change in p53 conformation remain to be clarified. Thus, we 
assume that dysfunction in the DDR to oxaliplatin-induced DSBs is the main reason for the 
increased sensitivity to the oxaliplatin-based regimens.
In our study, the PIN1 rs2233678 G/G variant had potential opposite effects on sensitivity to 
oxaliplatin and irinotecan between the Ox-cohort 1 and Iri-cohort 1; these findings are 
sustained by previous reports 18,19 that PIN1 isomerization of CK2α inhibits Top1 activity 
(Figure 1D). Given the effect was not confirmed in the Iri-cohort 2, a further validation study 
is warranted to explore whether the PIN1-mediated isomerization of CK2α varying Top1 
activity is associated with clinical outcome. Intriguingly, the combination cohort and Iri-
cohort 1 in the TRIBE trial had comparable effects on PFS and OS in patients with any PIN1 
rs2233678 C allele, whereas patients carrying the G/G variant continued to have a significant 
advantage in adding oxaliplatin to irinotecan. Consequently, we assume that the preferable 
effect of oxaliplatin is most likely to appear in patients with the G/G variant when receiving 
oxaliplatin-based treatment, and which confers improved outcomes when combining 
oxaliplatin to irinotecan-based treatment.
Our study has some limitations. The sample size was limiting for detecting small 
percentages of minor alleles. For example, there was no statistical significance in PFS for 
PIN1 rs2233678 in the Ox-cohort 2; however, the trend in HR was consistent with that in 
Ox-cohort 1 as well as tumor response. Nevertheless, we need a further study to confirm the 
predictive value of PIN1 rs2233678 for oxaliplatin-based treatment. The study lacked in 
vitro and in vivo results. The patients in the oxaliplatin cohorts were Asian (Japanese) while 
those in the irinotecan cohorts were Caucasians (Italian or German); and the population 
homogeneity in each cohort might have affected the allele frequency and outcomes. 
However, we observed no significant associations between PIN1 rs2233678 genotypes and 
other prognostic variables at baseline in our study. In contrast, our study has a number of 
strengths, including the presence of cohorts derived from two phase III studies, the presence 
of validation cohorts with comparable baseline characteristics, immunochemical 
confirmation of correlations between PIN1 genotype and protein expression. In addition, the 
superiority of FOLFOXIRI to FOLFIRI in PFS and OS in the phase III TRIBE trial was 
reproduced, when the study population was limited to patients carrying the PIN1 rs2233678 
G/G variant. This strongly suggests the clinical importance of oxaliplatin in combination 
treatment in first-line treatment for mCRC.
In conclusion, germline PIN1 polymorphisms may predict especially oxaliplatin sensitivity 
rather than irinotecan in mCRC patients. Further validation studies comparing oxaliplatin- or 
irinotecan-based treatment to combination treatment is warranted to verify the unique 
multifunctionality of PIN1 SNPs for providing an optimal treatment plan for selected 
patients.
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Figure 1. 
Chemotherapeutic agents and PIN1-related pathways: roles of PIN1 in (A) oxaliplatin-based 
treatment; (B) irinotecan-based treatment; (C) PIN1 SNPs and oxaliplatin sensitivity; and 
(D) PIN1 SNPs and irinotecan sensitivity.
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Figure 2. 
Progression-free survival (PFS) and overall survival (OS) in three cohorts: oxaliplatin cohort 
1 (A); irinotecan cohort 1 (B); and combination cohort (C) according to G/G or any C PIN1 
rs2233678 alleles.
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Figure 3. 
Progression-free survival (PFS) and overall survival (OS) in treatment arms in TRIBE study 
according to G/G or any C PIN1 rs2233678 alleles: arm A receiving FOLFIRI + 
bevacizumab (irinotecan cohort 1); arm B receiving FOLFOXIRI + bevacizumab 
(combination cohort).
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